Free Trial
NASDAQ:CNTB

Connect Biopharma H1 2025 Earnings Report

Connect Biopharma logo
$2.07 0.00 (0.00%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$2.07 0.00 (0.00%)
As of 08/8/2025 06:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Connect Biopharma EPS Results

Actual EPS
N/A
Consensus EPS
-$0.22
Beat/Miss
N/A
One Year Ago EPS
N/A

Connect Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Connect Biopharma Announcement Details

Quarter
H1 2025
Time
Before Market Opens
Conference Call Date
Friday, September 5, 2025
Conference Call Time
9:30AM ET

Conference Call Resources

Connect Biopharma Earnings Headlines

#1 Pre-IPO Opportunity For 2025 [Take Action Now!]
James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opportunity is taking shape—one tied to what could be the largest IPO in history: Elon Musk’s Starlink. With the IPO rumored to launch as soon as this year, James has uncovered a backdoor method to potentially profit before it goes public—starting with as little as $50.
See More Connect Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Connect Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Connect Biopharma and other key companies, straight to your email.

About Connect Biopharma

Connect Biopharma (NASDAQ:CNTB) Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

View Connect Biopharma Profile

More Earnings Resources from MarketBeat